Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/297047


Worldwide Prescription Drug Market for Womens Health: Now and Future 2004-2009


Description: This report looks at the worldwide prescription drug market for women's health and estimates the market outlook to 2009. The research study shows that, while the global economy has had its ups and downs, this report projects that the market will grow to about $116 billion in 2009 and will grow at a rate of about 16.6% (CAGR).

Substantial unmet need exists in the women's health field and this report identifies the profitable marketing opportunities pharmaceutical companies can pursue by developing their businesses to include this market. In this report, we have identified diseases and conditions that particularly affect women at a rate of 55% or greater of the population of the industrialized world. As a result, women have some unique health needs. The women's broad range of healthcare needs makes them a more lucrative marketing target than men.

Readers receive detailed data and analysis about important worldwide pharmaceutical industry developments. The research report discusses the main therapeutic areas of women¹s diseases or conditions with a brief description of the disease; patient populations, incidence, prevalence and mortality; gives the drug market size by disease; market participants; current drug treatments and revenues; market trends; new Rx drug R&D pipeline and its potential year to launch.

Pharmaceutical and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous women's health pharmaceutical industry topics with interesting and useful findings. Over 37 tables and 15 figures illustrate the findings throughout this 'must have' study.

Detailed information about the business and R&D activities of the top pharmaceutical and biotechnology companies is listed in many areas of this report ­ including more than 29 company profiles. Each profile includes financial data, current Rx drugs, "female adjusted" revenue estimates by indication, late stage drugs in the pipeline and likely launch year.


Contents: 1. Introduction to the Women's Health Rx Drug Market
1.1 Overview
1.2 The Importance of Rx Drugs for Women¹s Health
1.2.1 Drugs Can Help Prevent Or Cure Diseases Such As Osteoporosis, HIV/AIDS, and others.
1.2.2 Help their quality of life
1.2.3 Women Are Usually The Caregiver And Health Care Decision-Makers In Their Family.
1.2.4 Women Have Different Drug Needs Than Men.
1.2.5 Osteoporosis Is Another Silent Disease In Women¹s Health.
1.2.6 Women Have Infertility Issues
1.2.7 And More
1.3 Main Drug Therapy Areas
1.3.1 Autoimmune Conditions
1.3.1.1 Rheumatoid Arthritis
1.3.1.2 Scleroderma
1.3.1.3 Sjogren¹s Syndrome
1.3.1.4 Systemic Lupus Erythematosus
1.3.1.5 Multiple Sclerosis
1.3.1.6 Chronic Idiopathic Thrombocytopenic Purpura
1.3.1.7 Chronic Fatigue Syndrome
1.3.1.8 Fibromyalgia
1.3.2 Cancer
1.3.2.1 Breast Cancer
1.3.2.2 Cervical Cancer
1.3.2.3 Ovarian Cancer
1.3.2.4 Uterine Cancer (same as Endometrial)
1.3.3 Gynecological Infections and STDs
1.3.3.1 HIV/AIDS
1.3.3.2 Bacterial Vaginosis
1.3.3.3 Chlamydia
1.3.3.4 Genital Herpes (HSV-1&2)
1.3.3.5 HPV Infection
1.3.3.6 Gonorrhea
1.3.3.7 Hepatitis B and C
1.3.3.8 Pelvic Inflammatory Disease
1.3.3.9 Syphilis
1.3.3.10 Yeast (Candida) Infections
1.3.4 Menopause and Hormones
1.3.4.1 Endometriosis
1.3.4.2 Uterine Fibroids
1.3.4.3 Menopause
1.3.4.4 Amenorrhea
1.3.4.5 Dysmenorrhea
1.3.5 Osteoporosis
1.3.6 Reproductive Related Therapies
1.3.6.1 Contraception
1.3.6.2 Infertility
1.3.7 Female Sexual Dysfunction
1.3.8 Urologic and Kidney
1.3.8.1 Incontinence
1.3.8.2 Interstitial Cystitis
1.3.8.3 Urinary Tract Infections
2. Women's Health Rx Drug Market View by Disease
2.1 Market Overview
2.2Autoimmune Conditions
2.2.1 Overview
2.2.2 Autoimmune Incidence, Prevalence, Mortality & Growth by Indication
2.2.3 Autoimmune Drug Treatments, Makers & Revenue by Indication
2.2.4 Autoimmune New Drug Pipeline by Indication
2.2.5 Important Finding (Special Note)
2.3 Cancer
2.3.1 Overview
2.3.2 Cancer Incidence, Prevalence, Mortality & Growth by Indication
2.3.3 Cancer Drug Treatments, Makers & Revenue by Indication
2.3.4 Cancer New Drug R&D Pipeline/Commercial Implication by Indication
2.3.5 Important Finding (Special Note)
2.4 Gynecological Infections and STDs
2.4.1 Overview
2.4.2 Gynecological Infections Incidence, Prevalence, Mortality & Growth by Indication
2.4.3 Gynecological Infections Drug Treatments, Makers & Revenue by Indication
2.4.4 Gynecological Infections & STD Drug R&D Pipeline by Indication
2.4.5 Important Finding (Special Note)
2.5 Menopause and Hormones
2.5.1 Overview
2.5.2 Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2003
2.5.3 Menopause & Hormone Drug Treatments, Makers & Revenue by Indication
2.5.4 Menopause & Hormone Drug R&D Pipeline by Indication
2.5.5 Important Finding (Special Note)
2.6 Osteoporosis
2.6.1 Overview
2.6.2 Osteoporosis Incidence, Prevalence, Mortality & Growth
2.6.3 Osteoporosis Drug Treatments, Makers & Revenue by Indication
2.6.4 Osteoporosis Drug R&D Pipeline & Commercial Implication Indication
2.6.5 Important Finding (Special Note)
2.7 Reproductive Related Therapies
2.7.1 Overview
2.7.2 Reproductive Incidence, Prevalence, Mortality & Growth by Indication
2.7.3 Reproductive Drug Treatments, Makers & Revenue by Indication
2.7.4 Reproductive Related Drug R&D Pipeline & Commercial Implication
2.7.5 Important Finding (Special Note)
2.8 Female Sexual Dysfunction
2.8.1 Overview
2.8.2 Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication
2.8.3 Female Sexual Dysfunction Drug Treatments, Makers & Revenue by Indication
2.8.4 Female Sexual Dysfunction Drug R&D Pipeline & Commercial Implication Indication
2.8.5 Important Finding (Special Note)
2.9 Urologic and Kidney
2.9.1 Overview
2.9.2 Urologic & Kidney Incidence, Prevalence, Mortality & Growth by Indication
2.9.3 Urologic & Kidney Drug Treatments, Makers & Revenue by Indication
2.9.4 Urologic & Kidney Drug R&D Pipeline & Commercial Implication Indication
2.9.5 Important Finding (Special Note)

3. Women's Health Rx Drug Market Size Forecast by Disease
3.1 Total Market Size Forecast 2004E-2009P
3.1.2 Forecast Methodology
3.2 Market Size Forecast by Disease Segment 2004E-2009E
3.2.1 Forecast for 'Autoimmune' Segment
3.2.2 Forecast for 'Cancer' Segment
3.2.3 Forecast for 'Gyn. Infections & STDs' Segment
3.2.4 Forecast for 'Female Sexual Dysfunction' Segment
3.2.5 Forecast for 'Menopause & Hormones' Segment
3.2.6 Forecast for 'Osteoporosis' Segment
3.2.7 Forecast for 'Reproductive Related' Segment
3.2.8 Forecast for 'Urological & Kidney' Segment
3.3 WH Market Size Forecast by Disease Segment Breakdown
3.3.1 Forecast for 'Autoimmune' Indications
3.3.2 Forecast for 'Cancer' Indications
3.3.3 Forecast for 'Female Sexual Dysfunction'
3.3.4 Forecast for 'Osteoporosis'
3.3.5 Forecast for 'Gynecological Infections & STD' Indications
3.3.6 Forecast for the 'Menopause and Hormones' Indications
3.3.7 Forecast for the 'Reproductive Related' Indications
3.3.8 Forecast the 'Urologic and Kidney' Indications
3.3.9 WH Rx Market Size Forecast by Disease Segment Breakdown 2004-2009 ($M)
3.4 Share of Market by Disease Segments, 2005 & 2009
3.5 Market Size Forecast by WW Regions
3.6 Top Ranking 3-5 Drug Makers By Disease in WW WH Market

4. Profiles of Pharma & Biotech Companies in Women's Health
4.1 Abbott Labs
4.2 Akzo Nobel
4.3 Allergan
4.4 Amgen
4.5 Astellas Pharma
4.6 AstraZeneca
4.7 Barr Labs
4.8 Bayer Healthcare
4.9 Biogen-Idec
4.10 Bristol-Myers Squibb
4.11 Chiron
4.12 Eli Lilly
4.13 Forest Laboratories
4.14 Genentech
4.15 Gilead Sciences
4.16 GlaxoSmithKline
4.17 Johnson & Johnson
4.18 Kyowa Hakko
4.19 Merck & Co
4.20 Novartis AG
4.21 Pfizer
4.22 Roche Group
4.23 Sanofi-Aventis
4.24 Schering AG
4.25 Schering-Plough
4.26 Serono AG
4.27 Shire Pharmaceutical
4.28 Solvay Pharmaceuticals
4.29 Takeda Chemical
4.30 Teva Pharmaceuticals
4.31 Warner Chilcott PLC
4.32 Watson Pharmaceuticals
4.33 Wyeth Pharmaceuticals

5. Appendix
5.1 Women's Health Industry Web Links

List of Tables

Table 1. Pct. of WW Female Population by Disease Incidence/ Prevalence
Table 2. Autoimmune Incidence, Prevalence, Mortality & Growth 2003E
Table 3. Autoimmune Incidence, Prevalence, Mortality & Growth 2004P
Table 4. Autoimmune Drugs, Makers & Revenue by Indication
Table 5. Autoimmune Drug R&D Pipeline & Commercial Implication Indication
Table 6. Cancer Incidence, Prevalence, Mortality & Growth 2003
Table 7. Cancer Incidence, Prevalence, Mortality & Growth 2004P
Table 8. Cancer Drugs, Makers & Revenue by Indication
Table 9. Cancer Drugs R&D Pipeline & Commercial Implication Indication
Table 10. GYN Infections Incidence, Prevalence, Mortality & Growth 2003
Table 11. GYN Infections Incidence, Prevalence, Mortality & Growth 2004P
Table 12. GYN Infection & STD Drugs, Makers & Sales by Indication
Table 13. GYN Infection & STD Drug R&D Pipeline by Indication
Table 14. Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2003
Table 15. Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2004P
Table 16. Menopause & Hormones Drugs, Makers & Revenue by Indication
Table 17. Menopause & Hormone Drug R&D Pipeline by Indication
Table 18. Osteoporosis Incidence, Prevalence, Mortality & Growth
Table 19. Osteoporosis Incidence, Prevalence, Mortality & Growth by Indication &2004
Table 20. Osteoporosis Drugs, Makers & Revenue by Indication
Table 21. Osteoporosis Drug R&D Pipeline & Commercial Implication Indication
Table 22. Reproductive Incidence, Prevalence, Mortality & Growth by Indication
Table 23. Reproductive Incidence, Prevalence, Mortality & Growth 2004P
Table 24. Reproductive Drugs, Makers & Revenue by Indication
Table 25. Reproductive Related Drug R&D Pipeline & Commercial Implication
Table 26. Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication, 2003
Table 27. Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication, 2004
Table 28. Female Sexual Dysfunction Drugs, Makers & Revenue by Indication
Table 29. Female Sexual Dysfunction Drug R&D Pipeline & Commercial Implication Indication
Table 30. Urologic & Kidney Incidence, Prevalence, Mortality & Growth by Indication
Table 31. Urologic & Kidney Incidence, Prevalence, Mortality & Growth 2004P
Table 32. Urologic & Kidney Drugs, Makers & Revenue by Indication
Table 33. Urologic & Kidney Drug R&D Pipeline & Commercial Implication Indication
Table 34. Total WH Rx Market Size Forecast 2004E-2009E ($M)
Table 35. WH Rx Market Size Forecast by Disease Segment 2004E-2009P ($M)
Table 36. Share of Market by Disease Segments, 2005 & 2009
Table 37. Women¹s Health Rx Market Size Forecast by WW Regions
Table 38. Top Ranking 3-5 Current & New Pipeline Drug Makers By Disease

List of Illustrations

Figure 1. Worldwide Women's Health Rx Drug Market Map
Figure 2. Total Women's Health Rx Market Size Forecast 2004E-2009P
Figure 3. WH Rx Market Size Forecast by Disease Segment 2004E-2009P ($M)
Figure 4. Market Size by 'Autoimmune, Part 1' Indication Rx Revenues
Figure 5. Market Size by Autoimmune, Part 2' Indication Rx Revenues
Figure 6. Market Size by 'Cancer' Indication Rx Revenues
Figure 7. Market Size by 'Female Sexual Dysfunction' Rx Revenues
Figure 8. Market Size by Osteoporosis' Rx Revenues
Figure 9. Market Size by 'Gyn. Infections & STDs, Part 1' Indication Rx Revenues
Figure 10. Market Size by 'Gyn. Infections & STDs, Part 2' Indication Rx Revenues
Figure 11. Market Size by 'Menopause and Hormones' Indication Rx Revenues
Figure 12. Market Size by 'Reproductive Related' Indications Rx Revenues
Figure 13. Market Size by 'Urologic and Kidney' Indications Rx Revenues
Figure 14. Share of Market by Disease Segments, 2005 & 2009
Figure 15. Women's Health Rx Market Size Forecast by WW Regions To 2009


Companies Mentioned - Abbott Labs - Akzo Nobel - Allergan - Amgen - Astellas Pharma - AstraZeneca - Barr Labs - Bayer Healthcare - Biogen-Idec - Bristol-Myers Squibb - Chiron - Eli Lilly - Forest Laboratories - Genentech - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Kyowa Hakko - Merck & Co - Novartis AG - Pfizer - Roche Group - Sanofi-Aventis - Schering AG - Schering-Plough - Serono AG - Shire Pharmaceutical - Solvay Pharmaceuticals - Takeda Chemical - Teva Pharmaceuticals - Warner Chilcott PLC - Watson Pharmaceuticals - Wyeth Pharmaceuticals


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/297047

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 21/11/2008 21:39:07
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Worldwide Prescription Drug Market for Womens Health: Now and Future 2004-2009
Web Address:
http://www.researchandmarkets.com/reports/297047
Office Code:
OCIEFPNTURY

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €948.00 + EUR€ 50.00 Shipping/Handling *
Electronic (PDF) - 1 - 5 Users €1,425.00
Electronic (PDF) - Enterprisewide €1,897.00

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 21/11/2008 21:39:07

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World